Regeneron Pharmaceuticals, Inc. (REGN)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 15:43 UTC · Figures derived from the full chain (2,626 contracts, 16 expirations) · IV own-history percentile appears after 60 recorded days (28 so far)
Expected move · Nov 20, 2026 (32 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±8.7% (range 715.66–852.26) by Nov 20, 2026. ATM straddle: 68.30 @ strike 785 · ATM IV: 36.6%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 705.57 | -10% | 82.0% | 18.0% |
| 744.77 | -5% | 66.2% | 33.8% |
| 783.97 | +0% | 47.8% | 52.2% |
| 823.16 | +5% | 30.7% | 69.3% |
| 862.36 | +10% | 17.6% | 82.4% |
Model-estimated probabilities of finishing above/below each level at expiration: estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Nov 20, 2026 · lognormal model with zero drift: an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Oct 23, 2026 | 4 | ±3.0% | 35.4% | 606 |
| Oct 30, 2026 | 11 | ±6.2% | 44.2% | 668 |
| Nov 06, 2026 | 18 | ±7.2% | 40.4% | 273 |
| Nov 13, 2026 | 25 | ±7.9% | 37.6% | 74 |
| Nov 20, 2026 | 32 | ±8.7% | 36.6% | 2,689 |
| Nov 27, 2026 | 39 | ±9.4% | 35.8% | 64 |
| Dec 18, 2026 | 60 | ±11.4% | 35.2% | 12.4K |
| Jan 15, 2027 | 88 | ±13.3% | 34.2% | 7,364 |
| Feb 19, 2027 | 123 | ±16.1% | 34.7% | 772 |
| Mar 19, 2027 | 151 | ±17.8% | 34.7% | 2,295 |
Open interest by strike · Nov 20
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 1,100 C · 1,1131,000 C · 1,0001,140 C · 542740 C · 449790 P · 349
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Daily closes; Financial Modeling Prep.
Track record
Full history →Of 93 recorded snapshot-versus-outcome comparisons so far, the close landed inside the expected range 50.5% of the time.
Past earnings reactions
Avg |reaction| 4.5% · median 4.3% (20 reports). Two-session close-to-close window; definition
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle
Healthcare · Biotechnology · NASDAQ · Profile: Financial Modeling Prep
Related securities · Healthcare
MRNA · IV 113.8%PFE · IV 26.6%UNH · IV 28.6%HIMS · IV 89.8%LLY · IV 40.9%JNJ · IV 24.1%